The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor

Journal of Immunology

Volumn 161, Issue 2, 1998, Pages 927-932

  Tannenbaum, Charles S ^a   Tubbs, Raymond ^a   Armstrong, David ^a   Finke, James H ^a   Bukowski, Ronald M ^a   Hamilton, Thomas A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE; INTERLEUKIN 12;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFECT; EFFECTOR CELL; GROWTH INHIBITION; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR GROWTH; TUMOR REGRESSION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOKINES, CXC; IMMUNE SERA; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-12; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PORE FORMING CYTOTOXIC PROTEINS; RNA, MESSENGER;

EID: 0032528446     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Sayers, T. J., T. A. Wiltrout, K. McCormick, C. Husted, and R. H. Wiltrout. 1990. Antitumor effects of α-interferon and γ-interferon on a murine renal cancer (Renca) in vitro and in vivo. Cancer Res. 50:5414.
2. Brunda, M. J., and R. B. Wright. 1986. Differential antiproliferative effects of combinations of recombinant interferons α and γ on two murine tumor cell lines. Int. J. Cancer 37:287.
3. Brunda, M. J., V. Sulich, and D. Bellatoni. 1987. The anti-tumor effect of recombinant interferon α or γ is influenced by tumor location. Int. J. Cancer 40: 807.
4. Mule, J. J., J. C. Yang, R. Lafreniere, S. Shu, and S. A. Rosenberg. 1987. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by systemic administration of high-dose recombinant interleukin-2. J. Immunol. 139:285.
5. Kedar, E. and E. Klein. 1992. Cancer immunotherapy: are the results discouraging? Can they be improved? Adv. Cancer Res. 59:245.
6. Tannenbaum, C. S., N. Wicker, D. Armstrong, R. Tubbs, J. Finke, R. M. Bukowski, and T. A. Hamilton. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:693.
7. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
8. Brunda, M. J. 1994. Interleukin-12. J. Leukocyte Biol. 55:280.
9. Brunda, M. J., and M. K. Gately. 1994. Antitumor activity of interleukin-12. Clin. Immunol. Immunopathol. 71:253.
10. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant interleukin-12 (IL-12) administration induces tumor regression in association with interferon-γ production. J. Immunol. 153:1697.
11. Brunda, M. J., L. Luistro, J. A. Hendrzak, M. Fountoulakis, G. Garotta, and M. K. Gately. 1995. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. 17:71.
12. Brunda, M. J., L. Luistro, L. Rumennik, R. B. Wright, M. Dvorozniak, A. Aglione, J. M. Wigginton, R. H. Wiltrout, J. A. Hendrzak, and A. V. Palleroni. 1996. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol. 38(Suppl.):S16.
13. Trinchieri, G. 1993. Interleukin-12 and its role in the generation of Th1 cells. Immunol. Today 14:335.
14. Trinchieri, G., and P. Scott. 1994. The role of interleukin 12 in the immune response, disease and therapy. Immunol. Today 15:460.
15. Manetti, R., P. Parronchi, M. G. Giudizi, M.-P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune response and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199.
16. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, F. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp. Med. 170:827.
17. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
18. Clark-Lewis, I., B. Dewald, M. Loetscher, B. Moser, and M. Baggiolini. 1994. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J. Biol. Chem. 269:16075.
19. Baggiolini, M., P. Loetscher, and B. Moser. 1995. Interleukin-8 and the chemokine family. Int. J. Immunopharmacol. 17:103.
20. Clark-Lewis, I., K.-S. Kim, K. Rajarathnam, J.-H. Gong, B. Dewald, B. Moser, M. Baggiolini, and B. D. Sykes. 1995. Structure-activity relationships of chemokines. J. Leukocyte Biol. 57:703.
21. Farber, J. M. 1990. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc. Natl. Acad. Sci. USA 87:5238.
22. Liao, F., R. L. Rabin, J. R. Yannelli, L. G. Koniaris, P. Vanguri, and J. M. Farber. 1995. Human Mig chemokine: biochemical and functional characterization. J. Exp. Med. 182:1301.
23. Loetscher, M., B. Gerber, P. Loetscher, S. A. Jones, L. Piali, I. Clark-Lewis, M. Baggiolini, and B. Moser. 1996. Chemokine receptor specific for IP10 and Mig: structure, function and expression in activated T lymphocytes. J. Exp. Med. 184:963.
24. Meltzer, M. S. 1976. Tumoricidal response in vitro of peritoneal macrophages from conventionally housed and germ-free nude mice. Cell. Immunol. 22:176.
25. Sonouchi, K., T. A. Hamilton, C. S. Tannenbaum, R. R. Tubbs, R. Bukowski, and J. H. Finke. 1994. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-α and interleukin-2. Am. J. Pathol. 4:747.
26. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680.
27. Sheibani, K., and R. R. Tubbs. 1984. Enzyme immunohistochemistry: technical aspects. Semin. Diag. Pathol. 1:235.
28. Chirgwin, J. M., R. J. Pryzbyla, R. J. MacDonald, and W. J. Rutter. 1979. Isolation of biologically active RNA from sources enriched in ribonuclease. Biochemistry 18:5295.
29. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor.
30. Hamilton, T. A., N. Bredon, Y. Ohmori, and C. S. Tannenbaum. 1989. IFN-γ and IFN-β independently stimulate the expression of lipopolysaccharide-inducible genes in murine peritoneal macrophages. J. Immunol. 142:2325.
31. Tannenbaum, C. S., T. J. Koerner, M. M. Jansen, and T. A. Hamilton. 1988. Characterization of lipopolysaccharide-induced macrophage gene expression. J. Immunol. 140:3640.
32. Alexander, J. P., S. Kudoh, K. A. Melsop, T. A. Hamilton, M. G. Edinger, R. R. Tubbs, D. Sica, L. Tauson, E. Klein, R. M. Bukowski, and J. H. Finke. 1993. T cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce IL-2 and express IL-2 receptors. Cancer Res. 53:1380.
33. Taub, D. D., A. R. Lloyd, K. Conlon, J. M. Wang, J. R. Ortaldo, A. Harada, K. Matsushima, D. J. Kelvin, and J. J. Oppenheim. 1993. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med. 177:1809.
34. Podack, E. R., H. Hengartner, and M. G. Lichtenheld. 1991. A central role of perform in cytolysis? Annu. Rev. Immunol. 9:129.
35. Cesano, A., S. Visonneau, S. C. Clark, and D. Santoli. 1993. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J. Immunol. 151:2943.
36. Salcedo, T. W., L. Azzoni, S. F. Wolf, and B. Perusia. 1993. Modulation of perform and granzyme messenger RNA expression in human natural killer cells. J. Immunol. 151:2511.
37. Lowin, B., F. Beermann, A. Schmidt, and J. Tschopp. 1994. A null mutation in the perform gene impairs cytolytic T-lymphocyte and natural killer cell mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 91:11571.
38. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferon inducible protein IP-10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182:155.
39. Luster, A. D., S. M. Greenberg, and P. Leder. 1995. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182:219.
40. Farber, J. M. 1997. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukocyte Biol. 61:246.
41. Strieter, R. M., P. J. Polverini, S. L. Kunkel, D. A. Arenberg, M. D. Burdick, J. Kasper, J. Dzuiba, J. Van Damme, A. Walz, and D. Marriott. 1995. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270:27348.
42. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by IL-12. J. Natl. Cancer Inst. 87:581.
43. Sgadari, C., A. L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87:3877.
44. Ozmen, L., M. Pericin, J. Hakimi, R. A. Chizzonite, M. Wysocka, G. Trinchieri, M. Gately, and G. Garotta. 1994. Interleukin 12, interferon-γ, and tumor necrosis factor α are the key cytokines of the generalized Shwartzman reaction. J. Exp. Med. 180:907.
45. Orange, J. S., T. P. Salazar-Mather, S. M. Opal, R. L. Spencer, A. H. Miller, B. S. McEwen, and C. A. Biron. 1995. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J. Exp. Med. 181:901.
46. Hendrzak, J. A., and M. J. Brunda. 1995. Interleukin-12: biologic activity, therapeutic utility, and role in disease. Lab. Invest. 72:619.
47. Luster, A. D., and P. Leder. 1993. IP-10, A C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178:1057.
48. Strieter, R. M., P. J. Polverini, D. A. Arenberg, A. Walz, G. Opdenakker, J. Van Damme, and S. L. Kunkel. 1995. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukocyte Biol. 57:752.
49. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, S. B. Morris, M. D. Burdick, M. C. Glass, D. T. Taub, M. D. Iannettoni, T. I. Whyte, and R. M. Strieter. 1996. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184:981.
50. Sgadari, C., A. Angiolillo, B. W. Cherney, S. E. Pike, J. M. Farber, L. G. Koniaris, P. Vanguri, P. R. Burd, N. Sheik, G. Gupta, J. Teruya-Feldstein, and G. Tosato. 1996. Interferon inducible protein 10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA 93:13791.
51. Sgadari, C., J. M. Farber, A. L. Angiolillo, F. Liao, J. Teruya-Feldstein, P. R. Burd, L. Yao, G. Gupta, C. Kanegane, and G. Tosato. 1997. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 89:2635.
52. Huang, S., R. K. Singh, K. Xie, M. Gutman, K. K. Berry, C. D. Bucana, I. J. Fidler, and M. Bar-Eli. 1994. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol. Immunother. 39:231.
53. Huang, S., K. Xie, R. K. Singh, M. Gutman, and M. Bar-Eli. 1995. Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J. Interferon Cytokine Res. 15:655.
54. Manome, Y., P. Y. Wen, A. Hershowitz, T. Tanaka, B. J. Rollins, D. W. Kufe, and H. A. Fine. 1995. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol. Immunother. 41:227.
55. Rothenberg, M. E., A. D. Luster, and P. Leder. 1995. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc. Natl. Acad. Sci. USA 92:8960.
56. Laning, J., H. Kawasaki, E. Tanaka, Y. Luo, and M. Dorf. 1994. Inhibition of in vivo tumor growth by the β chemokine TCA3. J. Immunol. 153:4625.
57. Rollins, B., and M. E. Sunday. 1991. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol. Cell. Biol. 11:3125.
58. Mule, J. J., M. Custer, B. Averbook, J. C. Yang, J. S. Weber, D. V. Goeddel, S. A. Rosenberg, and T. J. Schall. 1996. RANTES secretion by gene modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther. 7:1545.
59. Dilloo, D., K. Bacon, W. Holden, W. Zhong, W. Burdach, A. Zlotnik, and M. Brenner. 1996. Combined chemokine and cytokine gene transfer enhances anti-tumor immunity. Nat. Med. 2:1090.